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Heart failureApoptosis, or programmed cell death, is an essential physiological process for proper embryogenesis aswell as for
homeostasis during aging. In addition, apoptosis is one of the major mechanisms causing cell loss in pathophys-
iological conditions such as heart failure. Thus, inhibition of apoptosis is an important approach for preventive
and therapeutic strategies. Here we show that the histone 3 lysine 4- and lysine 36-speciﬁc methyltransferase
Smyd2 acts as an endogenous antagonistic player of p53-dependent cardiomyocyte apoptosis. Smyd2 protein
levels were signiﬁcantly decreased in cardiomyocytes upon cobalt chloride-induced apoptosis or myocardial
infarction, while p53 expression was enhanced. siRNA-mediated knockdown of Smyd2 in cultured
cardiomyocytes further enhanced cobalt chloride-induced cardiomyocyte apoptosis. In contrast, Smyd2
overexpression resulted in marked methylation of p53 and prevented its accumulation as well as apoptotic cell
death in an Hsp90-independent manner. Moreover, overexpression, of Smyd2, but not Smyd2Y240F lacking a
methyl transferase activity, signiﬁcantly rescued CoCl2-induced apoptosis in H9c2 cardioblasts. Finally, Smyd2
cardiomyocyte-speciﬁc deletion in vivo promoted apoptotic cell death upon myocardial infarction, which
correlated with enhanced expression of p53 and pro-apoptotic Bax. Collectively, our data indicate Smyd2 as a
cardioprotective protein by methylating p53.farction; PARP, poly ADP ribose
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Apoptosis plays an important role in a variety of diseases including
ischemic heart disease, which often leads to heart failure, a major
cause of morbidity and mortality worldwide [1]. Thus, it is important
to identify new regulators of apoptosis. Smyd2 is a histone 3 lysine
4- and lysine 36-speciﬁc methyltransferase, which has been shownto repress p53-mediated apoptosis in response to various types of
DNA damage by methylation of the transcription factor p53 at lysine
370 [2,3]. This methylation causes dissociation of p53 from the
promoters of its target genes such as p21 (a cyclin-dependent protein
kinase important for cell-cycle control) [3].
Smyd2 belongs to the class of histone lysine methyltransferases
(HKMTs) that methylate lysine residues on histones and other proteins
to contribute to gene regulation. With the exception of the DOT1-like
histone H3 methyltransferase, all HKMTs contain a SET (Suppressor of
variegation, Enhancer of zeste, Trithorax) domain, required for
substrate binding and catalysis [4]. Based on the sequences surrounding
the SET domain, HKMTs have been divided into related subfamilies. One
of these subfamilies consists of ﬁvemembers (Smyd1–5) and is charac-
terized by inclusion of a MYND (Myeloid, Nervy and DEAF-1) domain
containing a zinc-ﬁnger motif, which contributes to protein–protein
interactions [5]. This zinc-ﬁnger motif plays an important role for the
transcriptional control of cell-cycle regulation, differentiation, proliferation
and muscle formation [6,7].
Members of the Smyd family exhibit several functions by not only
methylating histones but also a number of non-histone proteins. For
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(RB) [8], heat shock protein 90 (Hsp90) [9] and estrogen receptor
alpha (ERα) [10]. In the heart, the Smyd protein family appears to
play an important role. Targeted deletion of the founding member
Smyd1/Bop in mice disturbed maturation of ventricular cardiomyocytes
and affected proper right ventricular formation [11]. Subsequently, it
has been shown that Smyd1 and Smyd2 play an important role for
myoﬁbril organization and contraction of skeletal and cardiac muscle
in zebraﬁsh [9,12,13]. Smyd2 is transiently expressed during mouse
heart development. However, cardiomyocyte-speciﬁc deletion of
Smyd2 has suggested that Smyd2 is dispensable for proper mouse
heart development [14]. Whether Smyd2 plays a role in the pathophys-
iology of the heart remains unclear. Given that Smyd2 regulates
p53-mediated apoptosis and the clear implication of apoptotic regula-
tion in heart disease [15], the aim of this study was to analyze the role
of Smyd2 in cardiomyocyte apoptosis. We provide evidence for an
endogenous anti-apoptotic role of Smyd2 in cardiomyocytes in vitro
and in vivo identifying Smyd2 as a cardioprotective factor.
2. Material and methods
2.1. Animal model
All investigations conformwith the Guidelines for the Care and Use of
Laboratory Animals published by the USNational Institute of Health (NIH
publication No. 85-23, revised 1996) and were approved by the local
Animal Ethics Committee in accordance with governmental and interna-
tional guidelines on animal experimentation (Regierungspräsidium
Darmstadt, Hessen, Germany, Gen. Nr. B 2/231). Conditional Smyd2
knockout (cKO) mice harboring cardiomyocyte-speciﬁc deletion of
Smyd2 were generated by crossing Smyd2 ﬂoxed mice with mice
expressing Cre recombinase under the control of the Nkx-2.5 promoter
as described previously [14]. Mice were subjected to myocardial infarc-
tion (MI) by coronary artery occlusion. Sham-operated mice served as
controls (SHAM). Mice were euthanized at indicated time points after
MI for isolation of total RNA or immunohistochemistry. All surgical
procedures were performed as described recently [16]. In brief, mice
were anesthetized intraperitoneally by injection of ketamine
(100 mg/kg body weight) and xylazine (6 mg/kg body weight). Mice
were intubated endotracheally and ventilated with a rodent ventilator
(Hugo Sachs Electronics, Mach, Germany). A thoracotomy was
performed at the fourth intercostal space. All muscles overlying the
intercostal space were laid open and retracted with 5-0 silk threads;
the intercostal muscles were transected. A ligature with a 7-0 prolene
thread (Ethicon, Norderstedt, Germany) was placed around the left
anterior descending artery just below the atrioventricular border.
Discoloration of the ventricle and ECG-changes provided evidence of
ischemia. The lung was reinﬂated and muscle and skin layers were
closed separately. The animals were weaned by the respirator and
extubated. Sham-operated animals were subjected to similar surgery,
except that the ligature was not tied tightly.
2.2. Cardiomyocyte cell culture and induction of apoptosis
Neonatal ventricular cardiomyocytes of Sprague Dawley rats were
isolated from either postnatal day 1 or 3 and cultured as described
previously [17]. Neonatal cardiomyocytes were cultured for 48 h
in the presence of 5% horse serum and 20 μM of cytosine β-D-
arabinofuranoside (AraC) (Sigma-Aldrich) before stimulation or adenovi-
rus administration to prevent proliferation of non-myocytes (N90%
cardiomyocytes). Subsequently, cells were washed, serum starved for
12 h for synchronization, and then infected with adenovirus for 48 h. To
induce apoptosis, cardiomyocytes were then exposed to hypoxic stress
by culturing the cells in medium containing 750 μM Cobalt Chloride
(CoCl2) for 24 h (control: diluent DMSO). For inhibition of Hsp90,
cardiomyocytes were treated for 1 h with 17-AAG (100 nM) (Alexis)prior to the addition of CoCl2. To analyze protein degradation P1
cardiomyocytes were treated for 24 h with MG-132 (10 μM) (Sigma),
which was added 1 h before the addition of CoCl2 (750 μM).
2.3. H9c2 cells
H9C2 cells were grown at 37 °C in DMEM medium supplemented
with 10% fetal bovine serum, 2 mM Glutamax, 100 U/ml penicillin and
100 μg/ml streptomycin in a humidiﬁed 5% CO2 atmosphere. Cells
were transiently transfected using Lipofectamine® LTX reagent
according to the manufacturer's instructions. After 24 h of transfection,
cells were treated with 1 mM CoCl2 for 24 h.
2.4. Adenoviruses
Adenoviruses expressing β-Gal and Smyd2 (Applied Biological
Materials Inc.) under the control of a CMV promoter were utilized for
cardiomyocyte transfection (50 MOI per cell).
2.5. Evaluation of apoptosis
The prevalence of cardiomyocyte apoptosis was assessed utilizing
several assays: the CaspACE™ Assay System, Colorimetric (Promega),
the Annexin V-Cy3 apoptosis detection kit (BioVision) and terminal
deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling
(TUNEL) staining (Calbiochem). All assays were performed according
to the instructions of the manufacturers. Counting positive apoptotic
cardiomyocyte nuclei was performed in 7 independent ﬁelds of the
infarct border zone in the left ventricle at 3 distinct levels. To determine
the rate of apoptosis in H9c2 cells Annexin V & Dead Cell Assay was
performed utilizing Muse™ Cell Analyzer from Millipore following
manufacturer's instruction. Brieﬂy, after the indicated treatments, the
cells were incubated with Annexin V and Dead Cell Reagent (7-AAD)
and the events for dead, late apoptotic, early apoptotic, and live cells
were counted.
2.6. RNA isolation and RT-qPCR analyses
Total RNA from parafﬁn-embedded tissues was isolated from the
infarcted portions using the Recover All™ Total Nucleic Acid Isolation
Kit according to the manufacturer's instructions (Ambion). RNA from
neonatal cardiomyocytes or H9c2 cells was extracted using the RNeasy
Mini Kit (Qiagen). For Real-Time PCR analysis, cDNAwas ampliﬁedwith
IQTM SYBR® Green SuperMix (Biorad) and Bio-Rad iCYCLER iQ5. The
following primers were utilized: rat p53 forward: 5′-GACGCTGCCCCC
ACCATGAG-3′, reverse: 5′-ACCACCACGCTGTGCCGAAA-3′; mouse p53
forward: 5′-AGCAGGGCTCACTCCAGCTACC-3′, reverse: 5′-AGTCAGGC
CCCACTTTCTTGACC-3′; rat Smyd2 forward: 5′-CTACCCCGTGTACTCCCT
CA-3′, reverse: 5′-CTGGGGTGACTGTGAGGTTT-3′; rat Hif1 forward:
5′-GCCACACTGCGGCTGGTTAC-3′, reverse: 5′-GCCACACTGCGGCTGGTT
AC-3′; 18S RNA forward: 5′-ACCGCAGCTAGGAATAATGGA-3′, reverse:
5′-GCCTCAGTTCCGAAAACCA-3′; rat gapdh forward: 5- CAGAAGACTG
TGGATGGCCC-3, reverse: 5-AGTGTAGCCCAGGATGCCCT-3. Real-Time
PCR was performed in triplicates and relative gene expression was
calculated on the basis of ΔCt values to 18S RNA or gapdh.
2.7. Protein analysis
Whole cell lysates (50–100 μg) were separated by SDS-PAGE.
Protein concentrations were determined using Biorad DC protein
assay (Biorad). Equal amounts of proteins were resolved using NuPAGE
Novex Bis-Tris Gels (Invitrogen) blotted onto nitrocellulosemembranes
and incubated with primary antibodies. Following primary antibodies
were utilized: rabbit anti-Smyd2 (1:800), mouse anti-p53 (1C12)
(1:1000), rabbit anti-p53K370me1 (1:1000) [3], rabbit anti-PARP
(1:1000), rabbit anti-Hsp90 (1:800), rabbit anti-Bcl2 (1:800) and rabbit
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complexes were visualized using horseradish peroxidase-conjugated
secondary antibodies (Amersham) and SuperSignal ® ECL detection
system (BioRad).
2.8. Immunohistochemistry
H9c2 cells were ﬁxed with 3.7% formaldehyde (Sigma) for 15 min,
permeabilized with 0.5% Triton X-100/PBS for 10 min, blocked with
blocking buffer (5% goat serum, 0.2% Tween-20 in PBS) for 20 min and
incubated for 1 h with anti Myc-Tag (9B11) antibody (Cell Signaling)
diluted 1:2000 in blocking buffer. All steps were carried out at room
temperature. Either ALEXA 488- or ALEXA 594-conjugated antibodies
(1:200, Molecular Probes) were used to detect immune complexes.
4′,6′-diamidino-2-phenylindole (DAPI, Sigma) (0.5 mg/mL PBS) was
used to visualize DNA. For immunohistochemical analysis, the slides
were deparafﬁnized and rehydrated. Endogenous peroxidase was
blocked by immersing tissue sections in methanol containing 3% H2O2,
followed by washing in PBS. Non-speciﬁc antigens were blocked by
incubation of the tissue sections with 2.5% (v/v) horse serum for
20 min. The sections were then incubated for overnight at 4 °C with
rabbit polyclonal anti-Bax antibody (Santa Cruz). After extended
washing in PBS, primary antibody staining was visualized using the
VECTASTAIN ABC Kit with Nova RED (Vector Laboratories). Tissue
sections were counterstained with hematoxylin, dehydrated and
mounted.
2.9. siRNA interference
siRNA-mediated gene knockdownwas performed by using 50 nMof
siRNAs against Smyd2 and p53. As negative control the AllStars
Negative Control siRNA (Qiagen) was utilized. siRNAs were transfected
into freshly isolated neonatal cardiomyocytes by electroporation
(Amaxa) [18]. siRNAswere designed and synthesized by Qiagen against
Smyd2mRNA (Smyd2: 5′-CAGGAACGACCGGTTAAGAGA-3′) and p53
mRNA (Tp53: 5′-CAC GTA CTC AAT TTC CCT CAA-3′).
2.10. Statistical analyses
For immunoﬂuorescence analyses, 200 to 300 cardiomyocyte nuclei
per experiment were counted. Data are expressed as mean ± SEM of atPARP 116
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Fig. 1. Smyd2 is downregulated under apoptotic conditions in neonatal rat ventricular cardiom
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mean ± SEM, n = 3.least three independent experiments. The data were analyzed using
GraphPad Prism (version 4.00, GraphPad Software, Inc.). The statistical
signiﬁcance of differences was evaluated by either a Student's t-test or
one-way ANOVA for multiple comparisons followed by Bonferroni's
post hoc test. A difference of p b 0.05 was considered statistically
signiﬁcant.3. Results
3.1. Smyd2 is downregulated upon apoptosis induction
Smyd2 is expressed in postnatal cardiomyocytes [14] and is known
to inhibit p53-mediated apoptosis by methylation upon DNA damage
[3]. To test the hypothesis that Smyd2 regulates p53-mediated
apoptosis in cardiomyocytes, apoptosis was induced by CoCl2 [15,19].
CoCl2 treatment resulted in signiﬁcant downregulation of Smyd2
protein expression (Fig. 1A, B). Consistent with the induction of apopto-
sis, CoCl2 resulted in a marked accumulation of p53 and downregulation
of poly ADP ribose polymerase (PARP), a DNA-binding enzyme involved
in DNA damage processing and apoptosis [20,21] (Fig. 1A, B). In addition,
Hsp90, which can promote pro- as well as anti-apoptotic effects [19,22],
was downregulated. To better understand how Smyd2 expression is
regulated upon apoptosis induction we measured RNA expression levels
(Fig. 1C) and utilized the proteasome inhibitor MG-132 (Fig. 1D). Our
data suggest that Smyd2 expression upon CoCl2-induced apoptosis is
regulated at the transcriptional level but also through a proteasome-
dependent pathway.
To determine if downregulation of Smyd2 before induction of
apoptosis enhanced apoptosis, we targeted Smyd2, and as a control
p53, with siRNA. Western blot analyses conﬁrmed high efﬁciencies of
both knockdowns in cardiomyocytes (Fig. 2A). As p53 knockdown did
not affect Smyd2 expression, p53 appears not to be anupstreamregulator
of Smyd2 expression (Fig. 2A). Apoptosis was induced 48 h after siRNA
transfection (Fig. 2B) and quantiﬁed 24 h later by staining with
Ca2+-dependent phospholipid-binding Annexin V. As expected,
p53 knockdown protected cardiomyocytes from CoCl2-induced
apoptosis (Fig. 2C). In contrast, Smyd2 knockdown signiﬁcantly
increased the number of Annexin V-positive cells (Fig. 2C). Taken
together, these data suggest that Smyd2 might have an anti-apoptotic
function in cardiomyocytes.yd2
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To further strengthen the hypothesis that Smyd2 is an endogenous
anti-apoptotic factor in cardiomyocytes we tested whether ectopic
overexpression of Smyd2 would affect cardiomyocyte survival upon
CoCl2 treatment. Smyd2 overexpression in neonatal cardiomyocytes
was achieved by adenovirus infection [23] with a transduction
efﬁciency of N90% (Fig. 3A). CoCl2 treatment in control-infected
cardiomyocytes (Ad-β-Gal) marked increased expression of p53 and
reduced expression of the anti-apoptotic protein Bcl2 (Fig. 3B–D).
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(Fig. 3B–D). Furthermore, Smyd2 reduced caspase-3 activity in
CoCl2-treated cardiomyocytes (Fig. 3E). Finally, overexpression of
Smyd2 resulted in a signiﬁcant lower number of Annexin V-positive
cardiomyocytes compared to the Ad-β-Gal control virus (Fig. 3F).
Taken together, these data demonstrate that Smyd2 acts as an anti-
apoptotic factor in cardiomyocytes.
As Smyd2 is known to inhibit p53-mediated apoptosis upon DNA
damage bymethylation [3]we testedwhether p53 can also bemethylated
in cardiomyocytes. Overexpression of Smyd2 resulted in amarked increase
in p53 methylation, as demonstrated by Western Blot analysis using anap
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activity of Smyd2 is required for its anti-apoptotic effect we utilized the
rat cardioblast cell line H9c2. As in primary rat cardiomyocytes,
CoCl2-induced apoptosis resulted in H9c2 cells in downregulation of
Smyd2 (Supplemental Fig. 1A). Overexpression of Myc-Smyd2 in
H9c2 cells signiﬁcantly rescued CoCl2-induced apoptosis (Fig. 3H). In
contrast, overexpression of Myc-Smyd2Y240F, a Smyd2mutant lacking
methyl transferase activity [6], had no anti-apoptotic effect (Fig. 3H).
The transfection efﬁciency (60% for both plasmids) was tested in
parallel based on Myc expression. Collectively, these data suggest that
Smyd2 also inhibits CoCl2-induced apoptosis by methylation of p53.3.3. The anti-apoptotic effect of Smyd2 is independent of Hsp90
Previously, it has been demonstrated that Hsp90 can promote
pro- as well as anti-apoptotic effects [19,22]. Hsp90 is methylated by
Smyd2 [5], which has been shown to be important for the stability of
sarcomeric titin and muscle function [9,13]. However, it was unknown
whether Hsp90 played a role as mediator of the anti-apoptotic effect
of Smyd2. To determine the role of Hsp90, the Hsp90 inhibitor
17-allylamino-17-demethoxy geldanamycin (17-AAG) was utilized.
As previously shown 17-AAG (100 nM) treatment markedly decreased
CoCl2-induced apoptosis in neonatal cardiomyocytes as determined by
Annexin V staining [19] but could not enhance the protective effect of
p53 knockdown (Fig. 4A). In addition, 17-AAG abolished the
pro-apoptotic effect of Smyd2 knockdown (Fig. 4A). To determine
whether Smyd2 mediates its anti-apoptotic effect via Hsp90 we
performed Smyd2 overexpression experiments in the presence and
absence of 17-AAG. Ectopic overexpression of Smyd2, but not β-Gal
control protected cardiomyocytes from CoCl2-induced apoptosis as
determined by Annexin V staining (Fig. 4B, C). While 17-AAG treatment
signiﬁcantly reduced the number of Annexin V-positive cardiomyocytes
infectedwith the control adenovirus Ad-β-Gal, it had no signiﬁcant effect
on the anti-apoptotic effect of ectopic Smyd2 (Fig. 4B, C). These dataCA
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(B) Quantitation of Annexin V staining of P1 cardiomyocytes 72 h after infection with adenovir
or absence of the Hsp90 inhibitor 17-AAG. Note: Smyd2 overexpression signiﬁcantly decreased
was not disrupted upon 17-AAG treatment indicating that Smyd2 mediates its protective effec
pictures for Annexin V staining utilized for the quantiﬁcation in (B). Scale bars: 50 μm.indicate that the anti-apoptotic function of Smyd2 is independent of
active Hsp90.3.4. Smyd2 is required to limit p53-mediated apoptosis in the heart after
injury
Cardiomyocyte apoptosis plays a major role in heart failure [1]. To
assess whether Smyd2 is involved in the progression of heart failure,
the expression levels of Smyd2 were determined after MI in mice,
induced by ligation of the left anterior descending artery (LAD).
Smyd2 protein expression levels dropped at day one after MI and
remained at lower levels compared to SHAM-operated animals
(Fig. 5A and Supplemental Fig. 1B, C). Concomitantly, the levels of
methylated p53 were downregulated while the total level of p53 was
markedly increased at day one after MI as previously shown [19]. In
addition, PARP levels were decreased (Fig. 5A and Supplemental
Fig. 1). These data suggest that Smyd2 methylates p53 also in vivo.
Previously, we observed that Smyd2 is not required for heart
development and cardiac physiology [14]. To determine the effect of
cardiomyocyte-speciﬁc elimination of Smyd2 in cardiac pathophysiology
we performed MI studies in conditional Smyd2 knockout mice (Smyd2
cKO) harboring a cardiomyocyte-speciﬁc Smyd2 deletion. Smyd2 cKO
displayed signiﬁcantly elevated numbers of terminal deoxynucleotidyl
transferase (TdT)-mediated dUTP nick end labeling (TUNEL)-positive
cardiomyocytes at the infarct border zone (Fig. 5B, C). RT-qPCR analyses
of RNA isolated from infarcted regions revealed an approximate 2-fold
induction in the expression of p53 in Smyd2 cKO in comparison with
Smyd2ﬂ/ﬂ control littermates (Fig. 5D). Note, that p53 mRNA levels were
not altered in Sham-operated Smyd2 cKO mice (Fig. 5D). In addition,
immunohistochemistry analyses showed that the expression of the pro-
apoptotic protein Bax was markedly elevated in regions surrounding
the infarct areas of the LVs as compared to splenic control sections
(Fig. 5E). These data indicate that Smyd2 is required to limit the damage
to the heart in cardiac pathophysiology. Taken together, our data suggestAnnexin V/DAPI
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reduce p53-dependent cardiomyocyte apoptosis in cardiac disease.
4. Discussion
Our study identiﬁed a previously unrecognized endogenous
function of Smyd2 in limiting p53-mediated apoptosis in the heart
after injury. Several lines of evidence support this conclusion. Smyd2
is downregulated during cardiomyocyte apoptosis in vitro and Smyd2
knockdownenhancesCoCl2-induced apoptosis. In contrast, overexpression
of Smyd2 but not Smyd2Y240F abolishes CoCl2-induced apoptosis.
Finally, cardiomyocyte-speciﬁc ablation of Smyd2 enhances in vivo
cardiomyocyte apoptosis rates upon MI.
Previously, we reported that Smyd2 cKO exhibit under physiological
conditions no obvious phenotype [14]. However, it remained unclear
whether Smyd2 plays a role under pathophysiological conditions.
Recently, it was demonstrated that cytoplasmic Smyd2 is important
for sarcomeric organization and thus the maintenance of cardiac
function in zebraﬁsh bymethylating Hsp90 and promoting the interaction
of a Smyd2-methyl-Hsp90 complexwith titin [13]. In thepresent study,we
observed that Smyd2 expression, both in apoptotic cardiomyocytes
in vitro and in hearts after MI is downregulated and inversely correlated
with the expression levels of p53. The maximum activation of p53
expression was detected between 1 and 4 days after LAD closure, as
reported earlier [15]. Furthermore, Smyd2 was reported to represses
the apoptotic activity of p53 through methylation of lysine 370 [3].
Here we show that p53 is also methylated in the heart. Thus, we
hypothesized that Smyd2 might have a critical function in limiting
p53-mediated apoptosis in heart disease. This is important as
accumulating evidence points to a crucial role of p53 in stress-induced
apoptosis in the heart. Levels of p53 were shown to be upregulated
after ischemia–reperfusion [19,24] as well as in oxidative [25] andmechanical stress [15,26]. In addition, it has been demonstrated in
disease models that inhibition of p53 function is beneﬁcial for heart
function [15,19,27–29]. For example, targeted deletion of p53 as well
as overexpression of cardiomyocyte-restricted dominant-interference
p53 resulted in reduced levels of cardiomyocyte apoptosis and restored
cardiac function in acute doxorubicin cardiotoxicity [27,30].
Sham-operated Smyd2 cKOmice do not express altered levels of p53
(Fig. 5D). siRNA-mediated knockdown of p53 did not alter Smyd2
expression in primary rat cardiomyocytes (Fig. 2A). Neither inhibition
of Smyd2 degradation (Fig. 1C) nor overexpression of Smyd2 (resulting
in p53 methylation, Fig. 3G) had an obvious effect on p53 expression.
These data suggest that Smyd2-mediated methylation of p53 does not
effect the stability of p53 but rather its function. The observed correlation
of increased p53 levels to decreased levels of methylated p53 after MI
thus might be due to secondary effects (Fig. 5A).
Here we show by overexpression and knockdown experiments that
Smyd2 is a cardioprotective factor in p53-mediated apoptosis and thus
has an additional function in the heart besides sarcomeric organization.
This is also supported by the observation that the cardioprotective effect
of Smyd2 seems to be independent of Hsp90 in contrast to its role in
sarcomere function in cardiac and skeletalmuscle [9,13]. The chaperone
Hsp90 can interact with Smyd2 enhancing its methyltranferase activity
as well as its speciﬁcity in regard to H3K4 methylation, which is
essential for genes of cell cycle and transcription regulation [31].
Smyd2 interacts with the C-terminal dimerization domain of HSP90
methylating it at two distinct regions: K615 and K209 [5]. In addition
Smyd2 mediates H3K36 dimethylation in vitro, which in the absence
of Hsp90 is relatively weak [6], suggesting that H3K4 may be the
predominant site of methylation in vivo. However, we observed that
inhibition of Hsp90 with 17-AAG had no effect on the cardioprotective
effect of Smyd2, even though 17-AAG signiﬁcantly inhibited apoptosis
in cardiomyocytes as shown previously [19]. These data indicate that
2562 A. Sajjad et al. / Biochimica et Biophysica Acta 1843 (2014) 2556–2562the anti-apoptotic activity of Smyd2 is independent of Hsp90 and
suggest that the observed anti-apoptotic function of Smyd2 is exerted
through its nuclear activity in contrast to its cytoplasmic requirement
in sarcomeric organization.
Our data suggest that Smyd2 is not regulated by p53 and that Smyd2
does not affect p53 expression on a transcriptional level. However, we
conﬁrm here that Smyd2 can methylate p53 [3] and provide evidence
that the methylation activity of Smyd2 is required for its anti-apoptotic
effect in cardioblasts. In the future it will be interesting to determine if
also other targets of Smyd2 such as RB (lysine 860) [8] play a role in
cardiomyocyte apoptosis.
4.1. Conclusion
In the present study we have identiﬁed lysine methyltransferase
Smyd2 as an endogenous p53 antagonist in cardiomyocytes. Our data
indicate that Smyd2 is an anti-apoptotic factor acting independently
of Hsp90. Given our ﬁndings, inducing or maintaining Smyd2 expres-
sion or activating its downstream targets may be a useful therapy for
protecting patients from apoptosis-mediated cardiac disease and
therefore, warrants further preclinical investigation.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2014.06.019.
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